Stock BCAB BIOATLA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BioAtla, Inc.

Equities

BCAB

US09077B1044

Real-time Estimate Cboe BZX
Other stock markets
 11:35:31 2024-06-26 EDT 		5-day change 1st Jan Change
1.55 USD +1.31% Intraday chart for BioAtla, Inc. +10.60% -36.38%
05-23 BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting CI
05-15 Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
BioAtla to Participate in the Jefferies Global Healthcare Conference
AQ
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
BioAtla : BCAB_Corp_Update_May 2024_FINALv3
PU
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
AQ
BioAtla to Participate in the Citizens JMP Life Sciences Conference
AQ
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
AQ
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
AQ
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
AQ
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
AQ
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
GL
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
AQ
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
AQ
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
GL
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
AQ
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
GL
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
GL
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
GL
BioAtla to Participate in the Jefferies London Healthcare Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCAB Stock
  4. News BioAtla, Inc.
  5. Press Releases